MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09). On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Trading Up 4.0 %

Shares of MLTX stock opened at $42.37 on Thursday. The stock has a market cap of $2.71 billion, a P/E ratio of -32.84 and a beta of 1.28. The stock has a 50 day simple moving average of $46.90 and a 200 day simple moving average of $48.99. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26.

Wall Street Analyst Weigh In

Several research analysts have commented on MLTX shares. The Goldman Sachs Group upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $62.00 to $82.00 in a research report on Friday, January 17th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th. Finally, Wedbush restated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $84.20.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.